Viatris (VTRS)

Viatris, represented by the ticker symbol VTRS-Q, is currently under review by multiple experts who have expressed mixed sentiments. One expert appreciates its current trading valuation, noting a low price-to-earnings ratio of 7-8x, while also emphasizing the need for the company to concentrate more on enhancing shareholder value. Another expert points out that Viatris was spun out from Pfizer and has a relatively small market presence in the healthcare sector. They warn that they only consider companies in this field that are priced attractively. Overall, there is a recognition that Viatris has room for growth and potential, but its current performance and footprint may limit its appeal for some investors.